Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron

Tiger Newspress2021-12-16

Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).

A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.

Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).

Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Wkmk
2021-12-17
Wkmk
Like
XiuJ
2021-12-17
XiuJ
Like
来人
2021-12-17
来人
Nice
PearlynCSY
2021-12-17
PearlynCSY
Omicron cases now in 77 countries, spreading at unprecedented rate: WHO, Dec 15, 2021
ASMH
2021-12-17
ASMH
Like
- ASMH:
  O k
- ASMH:
  G reat
- XiuJ:
  Ok
Gladys8jk
2021-12-17
Gladys8jk
Ok
- 在於我們是:
  Ok!

发表看法

477

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1108384523?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-16 23:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108384523","market":"us","top_or_hot":-1,"title":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron","media":"Tiger Newspress","content":"<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron\n</h2>\n\n<h4 class=\"meta\">\n\n2021-12-16 23:09 北京时间&nbsp;&nbsp;&nbsp;<strong>Tiger Newspress</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv,...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":null,"article_id":"1108384523","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108384523","pubTimestamp":1639667369,"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"translate_title":"在对奥密克戎表现出中和作用后，Vir生物技术在早盘继续上涨超过7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). \nA significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. \nResearchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). \nData demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":690464152,"gmtCreate":1639702746738,"gmtModify":1639702746850,"author":{"id":"4101985304496410","authorId":"4101985304496410","name":"Wkmk","avatar":"https://static.tigerbbs.com/b5afff3c91027e319e71557d19d8b21b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4101985304496410","idStr":"4101985304496410"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690464152","repostId":1108384523,"repostType":4,"repost":{"id":"1108384523","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639667369,"share":"https://www.laohu8.com/m/news/1108384523?lang=&edition=full","pubTime":"2021-12-16 23:09","market":"us","language":"en","title":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1108384523","media":"Tiger Newspress","summary":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a","content":"<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108384523","content_text":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). \nA significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. \nResearchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). \nData demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":690469104,"gmtCreate":1639702193348,"gmtModify":1639702193782,"author":{"id":"3582013193139368","authorId":"3582013193139368","name":"XiuJ","avatar":"https://static.tigerbbs.com/2679b64d21b553ca13b45b2f03e15f76","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3582013193139368","idStr":"3582013193139368"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690469104","repostId":1108384523,"repostType":4,"repost":{"id":"1108384523","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639667369,"share":"https://www.laohu8.com/m/news/1108384523?lang=&edition=full","pubTime":"2021-12-16 23:09","market":"us","language":"en","title":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1108384523","media":"Tiger Newspress","summary":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a","content":"<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108384523","content_text":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). \nA significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. \nResearchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). \nData demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":690487209,"gmtCreate":1639701980958,"gmtModify":1639701981683,"author":{"id":"3575544575320394","authorId":"3575544575320394","name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3575544575320394","idStr":"3575544575320394"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690487209","repostId":1108384523,"repostType":4,"repost":{"id":"1108384523","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639667369,"share":"https://www.laohu8.com/m/news/1108384523?lang=&edition=full","pubTime":"2021-12-16 23:09","market":"us","language":"en","title":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1108384523","media":"Tiger Newspress","summary":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a","content":"<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108384523","content_text":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). \nA significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. \nResearchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). \nData demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":690574613,"gmtCreate":1639698050313,"gmtModify":1639698050906,"author":{"id":"4092458811577680","authorId":"4092458811577680","name":"PearlynCSY","avatar":"https://static.tigerbbs.com/b3e9fe7af061efe80a756d23de62e7b3","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"4092458811577680","idStr":"4092458811577680"},"htmlText":"Omicron cases now in 77 countries, spreading at unprecedented rate: WHO, Dec 15, 2021","listText":"Omicron cases now in 77 countries, spreading at unprecedented rate: WHO, Dec 15, 2021","text":"Omicron cases now in 77 countries, spreading at unprecedented rate: WHO, Dec 15, 2021","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690574613","repostId":1108384523,"repostType":4,"repost":{"id":"1108384523","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639667369,"share":"https://www.laohu8.com/m/news/1108384523?lang=&edition=full","pubTime":"2021-12-16 23:09","market":"us","language":"en","title":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1108384523","media":"Tiger Newspress","summary":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a","content":"<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108384523","content_text":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). \nA significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. \nResearchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). \nData demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":690541701,"gmtCreate":1639697138619,"gmtModify":1639697142350,"author":{"id":"3586939439858903","authorId":"3586939439858903","name":"ASMH","avatar":"https://static.tigerbbs.com/c8c22c3127769d9bb7b4e8d291d98433","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3586939439858903","idStr":"3586939439858903"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690541701","repostId":1108384523,"repostType":4,"repost":{"id":"1108384523","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639667369,"share":"https://www.laohu8.com/m/news/1108384523?lang=&edition=full","pubTime":"2021-12-16 23:09","market":"us","language":"en","title":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1108384523","media":"Tiger Newspress","summary":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a","content":"<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108384523","content_text":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). \nA significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. \nResearchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). \nData demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7038234,"gmtCreate":1639872399850,"gmtModify":1639872399879,"authorId":3586939439858903,"author":{"id":3586939439858903,"idStr":"3586939439858903","authorId":3586939439858903,"name":"ASMH","avatar":"https://static.tigerbbs.com/c8c22c3127769d9bb7b4e8d291d98433","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":690541701,"type":1,"supId":7016058,"prevId":0,"content":"O k","text":"O k","html":"O k"},{"id":7028766,"gmtCreate":1639785680267,"gmtModify":1639785680299,"authorId":3586939439858903,"author":{"id":3586939439858903,"idStr":"3586939439858903","authorId":3586939439858903,"name":"ASMH","avatar":"https://static.tigerbbs.com/c8c22c3127769d9bb7b4e8d291d98433","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":690541701,"type":1,"supId":7016058,"prevId":0,"content":"G reat","text":"G reat","html":"G reat"},{"id":7016058,"gmtCreate":1639702204112,"gmtModify":1639702204144,"authorId":3582013193139368,"author":{"id":3582013193139368,"idStr":"3582013193139368","authorId":3582013193139368,"name":"XiuJ","avatar":"https://static.tigerbbs.com/2679b64d21b553ca13b45b2f03e15f76","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":690541701,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":690555550,"gmtCreate":1639696742766,"gmtModify":1639696743233,"author":{"id":"4094787128284850","authorId":"4094787128284850","name":"Gladys8jk","avatar":"https://static.tigerbbs.com/789bbf473867763cd44be080e269826d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4094787128284850","idStr":"4094787128284850"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690555550","repostId":1108384523,"repostType":4,"repost":{"id":"1108384523","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639667369,"share":"https://www.laohu8.com/m/news/1108384523?lang=&edition=full","pubTime":"2021-12-16 23:09","market":"us","language":"en","title":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1108384523","media":"Tiger Newspress","summary":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a","content":"<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company&nbsp;announced&nbsp;new preclinical data, published to the preprint server&nbsp;bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).&nbsp;</p>\n<p>A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.&nbsp;</p>\n<p>Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved).&nbsp;</p>\n<p>Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with&nbsp;GlaxoSmithKline plc&nbsp;(NYSE:&nbsp;GSK), retained their in vitro neutralizing activity against omicron.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108384523","content_text":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). \nA significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. \nResearchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). \nData demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7014348,"gmtCreate":1639697486674,"gmtModify":1639697486781,"authorId":3580638845558081,"author":{"id":3580638845558081,"idStr":"3580638845558081","authorId":3580638845558081,"name":"在於我們是","avatar":"https://static.tigerbbs.com/400933d41d715fa2dc89a42f82e63f64","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":690555550,"type":1,"supId":0,"prevId":0,"content":"Ok!","text":"Ok!","html":"Ok!"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":477,"commentSize":72,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108384523"}